Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with <i>BRAF</i> V600E-mutant metastatic non-small-cell lung cancer?

J Thorac Dis · 2025 · PMC12780439 · PMID 41522121

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

did not reach statistical significanceP=0.13not close (p > 0.1)

In the weighted analysis, the hazard ratio for death was 0.56 (95% CI: 0.29–1.1), and the risk reduction with dabrafenib plus trametinib did not reach statistical significance (P=0.13) ( 14 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with &lt;i&gt;BRAF&lt;/i&gt; V600E-mutant metastatic non-small-cell lung cancer?

The sentences

Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with <i>BRAF</i> V600E-mutant metastatic non-small-cell lung cancer?